Who Should Receive a Wearable Defibrillator Vest at Hospital Discharge?

Area of Science:

• Cardiology
• Medical Devices
• Sudden Cardiac Death Prevention

Background:

• Implantable cardioverter-defibrillator (ICD) therapy is proven for ischemic cardiomyopathy.
• Benefits of ICDs in non-ischemic cardiomyopathy are less clear, but electrical cardioversion shows mortality benefits.
• The role of wearable cardioverter defibrillators (WCDs) in at-risk populations is not fully established.

Purpose of the Study:

• To review the role of WCD vests in preventing sudden cardiac death (SCD).
• To evaluate WCD efficacy in at-risk populations where ICD therapy is temporarily not indicated.

Main Methods:

• Review of randomized-controlled trials and meta-analyses on cardioverter-defibrillator therapy.
• Analysis of smaller cohort trials and the Vest Prevention of Early Sudden Death Trial (VEST).

Main Results:

• The VEST trial did not meet its primary endpoint of reducing arrhythmic death.
• However, the trial demonstrated significant differences in total mortality, suggesting a benefit.
• Previous smaller trials indicated WCD efficacy in specific patient groups.

Conclusions:

• WCD therapy shows promise for reducing total mortality in at-risk populations.
• Despite not meeting the primary endpoint, the VEST trial supports the continued use of WCDs.
• Further research and clinical application of WCDs are warranted for SCD prevention.